Last mentioned: Mar 21, 2026
Thursday Pre-Market
Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
FDA U-Turn
Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
Wednesday Pre-Market
Key reports from Analog Devices, Kraft Heinz, Garmin, Wix.com, and Wingstop.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
A diverse slate of market leaders across semiconductors, consumer goods, and energy are set to report results, providing a critical pulse check on industrial demand and consumer spending. Key reports from Analog Devices, Moderna, and Kraft Heinz will highlight the divergent paths of the tech recovery and the healthcare sector's post-pandemic transition.
Investors are navigating a complex Wednesday session as major players in biotech, semiconductors, and leisure release pivotal updates. Market attention is centered on Moderna's pipeline diversification and SanDisk's recovery in the memory sector, signaling a shift toward fundamental-driven trading.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
YieldMax has announced its latest round of monthly distributions for its suite of single-stock synthetic covered call ETFs, including those tracking MicroStrategy, Tesla, and Microsoft. The payouts reflect the varying volatility levels of the underlying assets, with MRNA and MSTR leading the distribution amounts.
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
This page surfaces every story mentioning Moderna across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Moderna was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |